Skip to main content
  • English
    • Nederlands
    • Français

Home
  • Sign In
  • Therapeutic areas
    • Cardiology
      • ASCVD
    • Dermatology
    • Hematology
      • ITP
    • Neurology
      • Multiple Sclerosis
    • Oncology
      • Breast Cancer
      • Prostate Cancer (mCRPC)
    • Ophthalmology
    • Respiratory
    • Rheumatology
  • Congresses & Events
    • Cardiology
      • BSC
      • ESC
    • Dermatology
      • EADV
      • Sharing is Caring
    • Hematology
      • ASH
      • EHA
      • ESH
    • Neurology
      • CMSC
      • EAN
      • ECTRIMS
    • Oncology
      • ASCO
      • ESMO
      • EBCC
      • SABCS
    • Rheumatology
      • Sharing is Caring
  • Contact

Popular Search

  • improved
  • improving
  • aimovig
  • migration
  • migraine

Recent News

RLTech and Nurse Academy
IMPACT event: Innovation and Multidisciplinary care with Pluvicto for Advanced mCRPC patients
Page protected by password
Search
Did you mean: action?
  • Indications - Cosentyx PsA

    Cosentyx (generic name: secukinumab) is a medication used to treat several autoimmune conditions. Here are the key indications for Cosentyx:

    1. Plaque Psoriasis:

    For adults with moderate to severe...

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of Action - Jakavi

    Uncontrolled JAK/STAT signalling is characteristic of both polycythaemia vera (PV) 1–5 and for myelofibrosis (MF). 6

    JAKs are tyrosine kinases that transmit signals from cytokine or growth factor receptors to the cell...
    Twitter Linkedin Facebook Pinterest Google plus
  • Clinical efficacy & safety

    The efficacy and safety 5 of iptacopan in adult patients with PNH were evaluated in two multicentre, open-label, 24-week phase III studies: an active comparator-controlled study (...

    Twitter Linkedin Facebook Pinterest Google plus
  • Indication - Kesimpta

    Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features 1

    Both newly diagnosed patients and patients switching from...

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of Action (MoA)

    Mechanism of Action (MoA)¹

    Iptacopan is a proximal complement inhibitor that targets Factor B (FB) to selectively inhibit the alternative pathway of the complement cascade. Inhibition of FB in the...

    Twitter Linkedin Facebook Pinterest Google plus
  • Safety Profile - Jakavi

    Below is a selection of the observed side effects; please refer to the SmPc or the package leaflet for the complete list.

    Myelosuppression

    Patients who develop anaemia may need blood transfusions. Dose adjustment or...
    Twitter Linkedin Facebook Pinterest Google plus
  • Reimbursement

    Twitter Linkedin Facebook Pinterest Google plus
  • Mechanism of action - Cosentyx PsA

    Cosentyx (secukinumab) is a fully human IgG1/κ monoclonal antibody that selectively binds to and neutralizes the proinflammatory cytokine interleukin-17A (IL-17A). 1 Cosentyx works by targeting IL-17A and inhibiting its interaction with...

    Twitter Linkedin Facebook Pinterest Google plus

Filter by specialism:

Subscribe to Novartis

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube
Sitemap
Cookie Settings
©2025 Novartis Belgium and Luxembourg
  • Terms of use
  • Privacy Policy
  • About cookies
This website is intended for health care professionals in Belgium and Luxembourg